- Home
- EMCG vs ELTX Comparison
EMCG vs ELTX Comparison
Compare EMCG & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- ELTX
- Stock Information
- Founded
- EMCG 2021
- ELTX 2011
- Country
- EMCG United States
- ELTX United States
- Employees
- EMCG N/A
- ELTX N/A
- Industry
- EMCG
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- EMCG
- ELTX Health Care
- Exchange
- EMCG NYSE
- ELTX Nasdaq
- Market Cap
- EMCG 83.7M
- ELTX 49.7M
- IPO Year
- EMCG 2022
- ELTX 2021
- Fundamental
- Price
- EMCG $11.60
- ELTX $4.16
- Analyst Decision
- EMCG
- ELTX Buy
- Analyst Count
- EMCG 0
- ELTX 2
- Target Price
- EMCG N/A
- ELTX $10.00
- AVG Volume (30 Days)
- EMCG 3.2K
- ELTX 16.1K
- Earning Date
- EMCG 01-01-0001
- ELTX 11-07-2024
- Dividend Yield
- EMCG N/A
- ELTX N/A
- EPS Growth
- EMCG 186.72
- ELTX N/A
- EPS
- EMCG 0.24
- ELTX N/A
- Revenue
- EMCG N/A
- ELTX N/A
- Revenue This Year
- EMCG N/A
- ELTX N/A
- Revenue Next Year
- EMCG N/A
- ELTX N/A
- P/E Ratio
- EMCG $48.18
- ELTX N/A
- Revenue Growth
- EMCG N/A
- ELTX N/A
- 52 Week Low
- EMCG $10.84
- ELTX $2.96
- 52 Week High
- EMCG $13.39
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- EMCG 73.32
- ELTX 40.82
- Support Level
- EMCG $11.47
- ELTX $4.05
- Resistance Level
- EMCG $11.62
- ELTX $4.89
- Average True Range (ATR)
- EMCG 0.01
- ELTX 0.28
- MACD
- EMCG 0.01
- ELTX -0.06
- Stochastic Oscillator
- EMCG 84.62
- ELTX 27.37
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.